Summary
138.54 0.38(0.28%)05/10/2024
Quest Diagnostics, Inc. (DGX)
Quest Diagnostics, Inc. (DGX)
Key Facts
| 1 Day | 1 Week | 1 Month | 3 Months | 6 Months | 1 Year | 5 Years | All Time |
| 0.99 | -0.86 | 5.34 | 7.50 | 3.09 | 2.78 | 53.55 | 5,148.28 |
Last 730 data points are shown. To view all data, Upgrade to PRO plan with only $1
| Trading Data | ||
| Close | 136.98 | |
| Open | 136.02 | |
| High | 137.15 | |
| Low | 135.41 | |
| Volume | 438,672 | |
| Change | 1.34 | |
| Change % | 0.99 | |
| Avg Volume (20 Days) | 1,057,406 | |
| Volume/Avg Volume (20 Days) Ratio | 0.41 | |
| 52 Week Range | 119.59 - 145.58 | |
| Price vs 52 Week High | -5.91% | |
| Price vs 52 Week Low | 14.54% | |
| Range | 0.71 | |
| Gap Up/Down | -2.09 | |
Fundamentals | ||
| Market Capitalization (Mln) | 15,377 | |
| EBIDTA | 1,775,000,064 | |
| PE Ratio | 18.6299 | |
| PEG Ratio | 1.5232 | |
| WallStreet Target Price | 147.00 | |
| Book Value | 57.9460 | |
| Earnings Per Share | 7.4300 | |
| EPS Estimate Current Quarter | 1.8500 | |
| EPS Estimate Next Quarter | 2.3500 | |
| EPS Estimate Current Year | 8.8300 | |
| EPS Estimate Next Year | 9.4700 | |
| Diluted EPS (TTM) | 7.4300 | |
| Revenues | ||
| Profit Marging | 0.0911 | |
| Operating Marging (TTM) | 0.1340 | |
| Return on asset (TTM) | 0.0620 | |
| Return on equity (TTM) | 0.1415 | |
| Revenue TTM | 9,287,000,064 | |
| Revenue per share TTM | 83.1050 | |
| Quarterly Revenue Growth (YOY) | 0.0150 | |
| Quarterly Earnings Growth (YOY) | -0.0340 | |
| Gross Profit (TTM) | 3,467,000,000 | |
| Dividends | ||
| Dividend Share | 2.8800 | |
| Dividend Yield | 0.0217 | |
| Valuations | ||
| Trailing PE | 18.6299 | |
| Forward PE | 14.6199 | |
| Price Sales (TTM) | 0.0000 | |
| Price Book (MRQ) | 2.2632 | |
| Revenue Enterprise Value | 2.0629 | |
| EBITDA Enterprise Value | 11.0197 | |
| Shares | ||
| Shares Outstanding | 111,092,000 | |
| Shares Float | 110,066,199 | |
| Shares Short | 0 | |
| Shares Short (Prior Month) | 0 | |
| Shares Ratio | 0.00 | |
| Short Outstanding (%) | 0.00 | |
| Short Float (%) | 0.03 | |
| Insider (%) | 0.43 | |
| Institutions (%) | 92.39 | |
05/07 12:26 EST - Zacks Investment Research
Quest Diagnostics (DGX) Grows in Digital Pathology With New Deal
Quest Diagnostics' (DGX) pathology laboratories nationwide are set to get a boost with PathAI's AISight digital pathology image management system.
Quest Diagnostics (DGX) Grows in Digital Pathology With New Deal
Quest Diagnostics' (DGX) pathology laboratories nationwide are set to get a boost with PathAI's AISight digital pathology image management system.
05/02 11:46 EST - Zacks Investment Research
Reasons to Retain Quest Diagnostics (DGX) Stock for Now
Investors are optimistic about Quest Diagnostics (DGX) on strong legacy business growth.
Reasons to Retain Quest Diagnostics (DGX) Stock for Now
Investors are optimistic about Quest Diagnostics (DGX) on strong legacy business growth.
05/02 10:05 EST - Zacks Investment Research
Quest Diagnostics (DGX) Inks Deal to Acquire PathAI Diagnostics
Quest Diagnostics' (DGX) latest transaction combines its oncology expertise and scale with PathAI's AI and digital pathology innovations.
Quest Diagnostics (DGX) Inks Deal to Acquire PathAI Diagnostics
Quest Diagnostics' (DGX) latest transaction combines its oncology expertise and scale with PathAI's AI and digital pathology innovations.
04/29 19:21 EST - Market Watch
FDA brings lab tests under federal oversight in bid to improve accuracy and safety
WASHINGTON — Makers of medical tests that have long escaped government oversight will have about four years to show that their new offerings deliver accurate results, under a government rule vigorously opposed by the testing industry.
FDA brings lab tests under federal oversight in bid to improve accuracy and safety
WASHINGTON — Makers of medical tests that have long escaped government oversight will have about four years to show that their new offerings deliver accurate results, under a government rule vigorously opposed by the testing industry.
04/23 10:56 EST - Zacks Investment Research
Quest Diagnostics (DGX) Q1 Earnings Top Estimates, Margins Down
Quest Diagnostics (DGX) continues its strong momentum of base business revenue growth in the first quarter of 2024.
Quest Diagnostics (DGX) Q1 Earnings Top Estimates, Margins Down
Quest Diagnostics (DGX) continues its strong momentum of base business revenue growth in the first quarter of 2024.
04/23 08:56 EST - Zacks Investment Research
Quest Diagnostics (DGX) Beats Q1 Earnings and Revenue Estimates
Quest Diagnostics (DGX) came out with quarterly earnings of $2.04 per share, beating the Zacks Consensus Estimate of $1.86 per share. This compares to earnings of $2.04 per share a year ago.
Quest Diagnostics (DGX) Beats Q1 Earnings and Revenue Estimates
Quest Diagnostics (DGX) came out with quarterly earnings of $2.04 per share, beating the Zacks Consensus Estimate of $1.86 per share. This compares to earnings of $2.04 per share a year ago.
04/23 08:02 EST - Reuters
Quest Diagnostics raises 2024 profit and revenue forecast on strong demand
Laboratory operator Quest Diagnostic raised its 2024 profit and revenue forecast on Tuesday after beating first-quarter estimates on robust demand for its diagnostic tests.
Quest Diagnostics raises 2024 profit and revenue forecast on strong demand
Laboratory operator Quest Diagnostic raised its 2024 profit and revenue forecast on Tuesday after beating first-quarter estimates on robust demand for its diagnostic tests.
04/16 11:06 EST - Zacks Investment Research
Earnings Preview: Quest Diagnostics (DGX) Q1 Earnings Expected to Decline
Quest Diagnostics (DGX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Earnings Preview: Quest Diagnostics (DGX) Q1 Earnings Expected to Decline
Quest Diagnostics (DGX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
04/15 10:51 EST - Zacks Investment Research
Quest Diagnostics (DGX) to Post Q1 Earnings: What's in Store?
Acquisitions and partnerships with health plans are expected to drive Quest Diagnostics' (DGX) base business performance in the first quarter of 2024.
Quest Diagnostics (DGX) to Post Q1 Earnings: What's in Store?
Acquisitions and partnerships with health plans are expected to drive Quest Diagnostics' (DGX) base business performance in the first quarter of 2024.
04/03 12:26 EST - Zacks Investment Research
Quest Diagnostics (DGX) Collaborates With Broad Clinical Labs
Quest Diagnostics (DGX) collaboration is intended to demonstrate the clinical value of WGS as a first-line genetic test for postnatal diagnosis of developmental delay disorders.
Quest Diagnostics (DGX) Collaborates With Broad Clinical Labs
Quest Diagnostics (DGX) collaboration is intended to demonstrate the clinical value of WGS as a first-line genetic test for postnatal diagnosis of developmental delay disorders.
03/28 21:11 EST - Seeking Alpha
8 Upcoming Dividend Increases
A list of top stocks expected to raise dividends in the upcoming week, with increases averaging 8.4% and median 6.8%. Companies included in the list have consistently grown their dividends for at least five years. Comparison of historical returns of stocks to benchmark SCHD, with JPM being the top performer.
8 Upcoming Dividend Increases
A list of top stocks expected to raise dividends in the upcoming week, with increases averaging 8.4% and median 6.8%. Companies included in the list have consistently grown their dividends for at least five years. Comparison of historical returns of stocks to benchmark SCHD, with JPM being the top performer.
03/19 15:06 EST - PRNewsWire
Quest Diagnostics to Release First Quarter 2024 Financial Results on April 23, 2024
SECAUCUS, N.J., March 19, 2024 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), a leader in diagnostic information services, announced that it will report first quarter 2024 financial results on Tuesday, April 23, 2024, before the market opens.
Quest Diagnostics to Release First Quarter 2024 Financial Results on April 23, 2024
SECAUCUS, N.J., March 19, 2024 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), a leader in diagnostic information services, announced that it will report first quarter 2024 financial results on Tuesday, April 23, 2024, before the market opens.
02/27 13:21 EST - Zacks Investment Research
Quest Diagnostics' (DGX) New Pact to Reduce Food Insecurity
Quest Diagnostics' (DGX) recent collaboration aims to advance food access and healthy eating habits for underserved communities.
Quest Diagnostics' (DGX) New Pact to Reduce Food Insecurity
Quest Diagnostics' (DGX) recent collaboration aims to advance food access and healthy eating habits for underserved communities.
02/23 09:35 EST - PRNewsWire
Quest Diagnostics to Speak at the Barclays 26th Annual Global Healthcare Conference
SECAUCUS, N.J. , Feb. 23, 2024 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), a leader in diagnostic information services, announced that Sam Samad, Executive Vice President and Chief Financial Officer, will speak on the company's strategy, performance and the latest market developments and trends during a fireside chat at the Barclays 26th Annual Global Healthcare Conference in Miami on Wednesday, March 13, 2024, at 10:15 a.m.
Quest Diagnostics to Speak at the Barclays 26th Annual Global Healthcare Conference
SECAUCUS, N.J. , Feb. 23, 2024 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), a leader in diagnostic information services, announced that Sam Samad, Executive Vice President and Chief Financial Officer, will speak on the company's strategy, performance and the latest market developments and trends during a fireside chat at the Barclays 26th Annual Global Healthcare Conference in Miami on Wednesday, March 13, 2024, at 10:15 a.m.
02/15 09:01 EST - Zacks Investment Research
Quest Diagnostics (DGX) Boosts Oncology Portfolio With New Test
Quest Diagnostics (DGX) debuts the MelaNodal Predict test in collaboration with SkylineDx.
Quest Diagnostics (DGX) Boosts Oncology Portfolio With New Test
Quest Diagnostics (DGX) debuts the MelaNodal Predict test in collaboration with SkylineDx.
02/13 09:21 EST - Zacks Investment Research
Quest Diagnostics (DGX) Debuts PFAS Blood Test Offering
Quest Diagnostics (DGX) introduces the first consumer-initiated blood test with physician consult on questhealth.com.
Quest Diagnostics (DGX) Debuts PFAS Blood Test Offering
Quest Diagnostics (DGX) introduces the first consumer-initiated blood test with physician consult on questhealth.com.
02/13 08:51 EST - Zacks Investment Research
3 Medtech Stocks Likely to Top Estimates This Earnings Season
Here are three stocks, GMED, GKOS and PRCT, which are expected to beat earnings estimates in the ongoing reporting cycle.
3 Medtech Stocks Likely to Top Estimates This Earnings Season
Here are three stocks, GMED, GKOS and PRCT, which are expected to beat earnings estimates in the ongoing reporting cycle.
02/05 05:36 EST - Seeking Alpha
Quest Diagnostics: Post-COVID Normalization Pretty Much Done
Quest Diagnostics is a leading provider of diagnostic information services, offering laboratory testing, genomics, and other diagnostic solutions. During 2020, COVID-19 detection tests played an important role in the atypical growth of the top line and the substantial increase in margins. This factor has already been completely normalized. From this base point, I expect low-single-digit organic growth and improved margins, which, together with a dividend yield of 2.4%, should be enough to obtain an attractive return.
Quest Diagnostics: Post-COVID Normalization Pretty Much Done
Quest Diagnostics is a leading provider of diagnostic information services, offering laboratory testing, genomics, and other diagnostic solutions. During 2020, COVID-19 detection tests played an important role in the atypical growth of the top line and the substantial increase in margins. This factor has already been completely normalized. From this base point, I expect low-single-digit organic growth and improved margins, which, together with a dividend yield of 2.4%, should be enough to obtain an attractive return.
02/01 11:42 EST - Seeking Alpha
Quest Diagnostics Inc. (DGX) Q4 2023 Earnings Call Transcript
Quest Diagnostics Inc. (DGX) Q4 2023 Earnings Call Transcript
Quest Diagnostics Inc. (DGX) Q4 2023 Earnings Call Transcript
Quest Diagnostics Inc. (DGX) Q4 2023 Earnings Call Transcript